174 related articles for article (PubMed ID: 20550533)
61. Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study.
Sagmeister MS; Taylor AE; Fenton A; Wall NA; Chanouzas D; Nightingale PG; Ferro CJ; Arlt W; Cockwell P; Hardy RS; Harper L
Clin Endocrinol (Oxf); 2019 Jan; 90(1):241-249. PubMed ID: 30358903
[TBL] [Abstract][Full Text] [Related]
62. Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.
Vetter H; Vetter W
Klin Wochenschr; 1975 Apr; 53(8):391-3. PubMed ID: 211313
[TBL] [Abstract][Full Text] [Related]
63. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
64. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity.
Gelding SV; Taylor NF; Wood PJ; Noonan K; Weaver JU; Wood DF; Monson JP
Clin Endocrinol (Oxf); 1998 Feb; 48(2):153-62. PubMed ID: 9579226
[TBL] [Abstract][Full Text] [Related]
65. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
Edelmann F; Schmidt AG; Gelbrich G; Binder L; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Eur J Heart Fail; 2010 Aug; 12(8):874-82. PubMed ID: 20538867
[TBL] [Abstract][Full Text] [Related]
66. Long-term magnesium supplementation improves glucocorticoid metabolism: A post-hoc analysis of an intervention trial.
Schutten JC; Joris PJ; Minović I; Post A; van Beek AP; de Borst MH; Mensink RP; Bakker SJL
Clin Endocrinol (Oxf); 2021 Feb; 94(2):150-157. PubMed ID: 33030273
[TBL] [Abstract][Full Text] [Related]
67. Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not oestrogen dependent.
Toogood AA; Taylor NF; Shalet SM; Monson JP
Clin Endocrinol (Oxf); 2000 Jan; 52(1):61-6. PubMed ID: 10651754
[TBL] [Abstract][Full Text] [Related]
68. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 and free fatty acid-induced insulin resistance.
Mai K; Kullmann V; Bobbert T; Maser-Gluth C; Möhlig M; Bähr V; Pfeiffer AF; Spranger J; Diederich S
Clin Endocrinol (Oxf); 2005 Oct; 63(4):442-9. PubMed ID: 16181237
[TBL] [Abstract][Full Text] [Related]
69. Angiotensin administration stimulates renal 11 beta-hydroxysteroid dehydrogenase activity in healthy men.
Kerstens MN; van der Kleij FG; Boonstra AH; Sluiter WJ; van der Molen JC; Navis G; Dullaart RP
Kidney Int; 2004 Jun; 65(6):2065-70. PubMed ID: 15149319
[TBL] [Abstract][Full Text] [Related]
70. Detailed analysis of cortisol, cortisone and their tetrahydro- and allo-tetrahydrometabolites in human urine by LC-MS/MS.
Kosicka K; Siemiątkowska A; Pałka D; Szpera-Goździewicz A; Bręborowicz GH; Główka FK
J Pharm Biomed Anal; 2017 Jun; 140():174-181. PubMed ID: 28359965
[TBL] [Abstract][Full Text] [Related]
71. 11beta-hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex.
Mazzocchi G; Rossi GP; Neri G; Malendowicz LK; Albertin G; Nussdorfer GG
FASEB J; 1998 Nov; 12(14):1533-9. PubMed ID: 9806762
[TBL] [Abstract][Full Text] [Related]
72. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
73. Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.
Bland R; Worker CA; Noble BS; Eyre LJ; Bujalska IJ; Sheppard MC; Stewart PM; Hewison M
J Endocrinol; 1999 Jun; 161(3):455-64. PubMed ID: 10333548
[TBL] [Abstract][Full Text] [Related]
74. Multicomponent gas chromatographic analysis of urinary steroids excreted by an infant with a defect in aldosterone biosynthesis.
Shackleton CH; Honour JW; Dillon M; Milla P
Acta Endocrinol (Copenh); 1976 Apr; 81(4):762-73. PubMed ID: 946566
[TBL] [Abstract][Full Text] [Related]
75. Role of atrial natriuretic peptide in mineralocorticoid escape phenomenon in patients with primary aldosteronism.
Nakamura T; Ichikawa S; Sakamaki T; Sato K; Kogure M; Tajima Y; Kato T; Murata K
Proc Soc Exp Biol Med; 1987 Sep; 185(4):448-54. PubMed ID: 2956609
[TBL] [Abstract][Full Text] [Related]
76. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial.
Matthesen SK; Larsen T; Vase H; Lauridsen TG; Jensen JM; Pedersen EB
Clin Exp Hypertens; 2013; 35(5):313-24. PubMed ID: 22966789
[TBL] [Abstract][Full Text] [Related]
77. Reduced 11beta-hydroxysteroid dehydrogenase type 1 activity in obese boys.
Wiegand S; Richardt A; Remer T; Wudy SA; Tomlinson JW; Hughes B; Grüters A; Stewart PM; Strasburger CJ; Quinkler M
Eur J Endocrinol; 2007 Sep; 157(3):319-24. PubMed ID: 17766714
[TBL] [Abstract][Full Text] [Related]
78. Treatment of polycystic ovary syndrome with spironolactone plus licorice.
Armanini D; Castello R; Scaroni C; Bonanni G; Faccini G; Pellati D; Bertoldo A; Fiore C; Moghetti P
Eur J Obstet Gynecol Reprod Biol; 2007 Mar; 131(1):61-67. PubMed ID: 17113210
[TBL] [Abstract][Full Text] [Related]
79. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
[TBL] [Abstract][Full Text] [Related]
80. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
Jensen J; Henik RA; Brownfield M; Armstrong J
Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
